1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > US Proton Therapy Market Outlook 2020

US Proton Therapy Market Outlook 2020

  • June 2015
  • -
  • RNCOS
  • -
  • 75 pages

In light of an alarmingly rising incidence of cancers and limited treatment options, physicians are being forced to look beyond conventional treatments. In such a scenario, Proton Therapy, the most advanced radiation technique available, is being projected as the Rolls Royce of Radiation Oncology. Unfortunately, access to proton therapy is limited for many patients due to a low number of proton therapy centers. Hence, many research institutions and hospitals have started investing in proton therapy to make it more accessible to patients.

According to the “US Proton Therapy Market Outlook 2020”, report by RNCOS, the United States will be home to 29 such centers by 2020. Consequently, the market will breach a Billion dollar mark to attain revenue of around US$ 1.22 Billion by 2020, growing at a CAGR of 11.4% during the forecast period (2014-2020). The report provides an insight into the cancer demographics of USA and the various possible causes for a high cancer incidence in the country. The document covers a historical trend (2008-2014) of cancer incidences, deaths and prevalence along with state-wide and site-wide cancer incidences in the country.

Based on a complex correlation-regression model accounting population demographics, disease statistics, macro & micro economic indicators of the country, etc., we have performed an opportunity assessment for the potential of proton therapy in the US. We have been able to draw the current and future demands for a number of proton therapy centers in the country. Not only this, the report enlists the top ten states with the maximum potential for a proton therapy center. The list provides an insight into the current and future scenarios of centers along with an estimation of the shortage of proton centers in each state which can help service providers and vendors to extract benefits from the largely untapped but lucrative market.

As for the market, the report provides a state-wide distribution of proton therapy centers in the US. A thorough analysis has been done on the existing and upcoming proton therapy centers to measure the market size and its future condition.

Following that, RNCOS was able to deduce various trends, drivers and challenges which would have a major influence in shaping the growing market. On the competitive front, the report covers the current stand of the market and its probable transformation by 2020 for service providers and equipment vendors. There is also a ‘strengths-weakness’ analysis of equipment vendors along with their business overviews, products & services, and existing & planned installations in US till 2020, thus making it a must read for consultants and companies planning to enter the market.

Table Of Contents

US Proton Therapy Market Outlook 2020
1. Analyst View
2. Research Methodology
3. US Cancer Demographics
3.1 Incidence by State
3.2 Incidence by Site
4. Current Radiation Therapies
4.1 Third Dimensional Conformal Therapy (CRT)
4.2 Image Guided Radiotherapy (IGRT)
4.3 Intensity Modulated Radiotherapy (IMRT)
4.4 Stereotactic Radiotherapy
4.5 Neutron Therapy
4.6 Proton Therapy
4.6.1 Why Proton Therapy?
5. Components of a Standard Proton Therapy Center
5.1 Proton Accelerator
5.2 Beam Transport System
5.3 Beam Delivery System
5.4 Nozzle
5.4.1 Single Scattering
5.4.2 Double Scattering
5.4.3 Uniform Scanning Nozzle
5.4.4 Pencil Scanning Nozzle
5.5 Treatment Planning System
5.6 Image Viewers
5.7 Patient Positioning System
5.8 Human Resource
6. US Proton Therapy Market Outlook to 2018
6.1 Current Market Size and Future Growth
6.2 Potential Patients by State (2014 and 2020)
6.2.1 Market Penetration
6.3 Analysis of Existing and Forthcoming Players
6.3.1 Service Providers
6.3.2 Equipment Providers
6.4 Opportunity Assessment
7. Market Trends
7.1 Increasing Centers with More Number of Treatment Rooms
7.2 Penetration of Smaller Proton Accelerators Increasing
8. Industry Drivers and Restraints
8.1 Drivers
8.1.1 Increasing Incidence of Cancer
8.1.2 Benefits over Conventional Therapies
8.2 Restraints
8.2.1 Reimbursement Issues
8.2.2 High Prices
9. Competitive Landscape and Strategic Analysis
9.1 IBA Group
9.2 Hitachi
9.3 Mevion Medical Systems
9.4 Varian

List of Figures:

Figure 4-1: Advantages of Proton Therapy over Conventional Radiation Therapy
Figure 5-1: Components of a Proton Therapy Center
Figure 6-1: Proton Therapy Market (Million US$), 2014-2020
Figure 6-2: Share of Proton Therapy Market in Potential Market (2014)
Figure 6-3: Share of Proton Therapy Market in Potential Market (2020)
Figure 6-4: Market Share of Service Providers (2014)
Figure 6-5: Market Share of Service Providers (2020)
Figure 6-6: Share of Vendors by Number of Proton Accelerators Installed in US Proton Therapy Centers (2014)
Figure 6-7: Share of Vendors by Number of Proton Accelerators Installed in US Proton Therapy Centers (2020)
Figure 6-8: Demand of Proton Therapy Centers (2014 and 2020)
Figure 6-9: Shortage of Proton Therapy Centers (2014 and 2020)
Figure 7-1: Proton Therapy Center by Number of Treatment Rooms (2014 and 2020)
Figure 7-2: Proton Therapy Center by Type of Proton Accelerator (2014 and 2020)
Figure 8-1: Cancer Incidence (Million), 2008-2014
Figure 8-2: Cancer Mortality ('000), 2008-2014
Figure 9-1: IBA: Breakdown of Revenue by Activity (2014)

List of Tables:

Table 3-1: Cancer Incidence by State (2008-2014)
Table 3-2: Cancer Incidence by Site (2008-2014)
Table 6-1: State-wide Potential Patients for Proton Therapy (2014)
Table 6-2: State-wide Potential Patients for Proton Therapy (2020)
Table 6-3: Proton Therapy Centers (2014)
Table 6-4: Upcoming Proton Therapy Centers (2015 to 2019)
Table 6-5: Proton Therapy Equipment Providers with number of Installations till 2014
Table 6-6: Proton Therapy Equipment Providers with Number of Installations by 2020
Table 6-7: Shortage of Proton Therapy Centers (2020)
Table 9-1: IBA - Proton Therapy Products and Services
Table 9-2: IBA - Key Financials (Million Euro), 2012-2014
Table 9-3: IBA - Existing and Upcoming Proton Therapy Installations
Table 9-4: IBA - Strengths and Weaknesses
Table 9-5: Hitachi - Key Financials (Billion US$), 2012-2014
Table 9-6: Hitachi - Existing and Upcoming Proton Therapy Installations
Table 9-7: Hitachi - Strengths and Weaknesses
Table 9-8: Mevion - Existing and Upcoming Proton Therapy Installations
Table 9-9: Mevion - Strengths and Weaknesses
Table 9-10: Varian - Proton Therapy Products and Services
Table 9-11: Varian - Key Financials (Billion US$), 2012-2014
Table 9-12: Varian: Proton Therapy Installations
Table 9-13: Varian - Strengths and Weaknesses

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

  • $ 9 495
  • Industry report
  • June 2016
  • by Global Data

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

  • $ 6 995
  • Industry report
  • June 2016
  • by GBI Research

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies Summary Diabetes is a common ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Sweden

  • September 2016
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Opioid and Therapy Market in the US

  • September 2016
    11 pages
  • Opioid  

    Therapy  

    Analgesic  

  • United States  

View report >

Opioid Market in the US

  • September 2016
    7 pages
  • Opioid  

  • United States  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.